Delays to Neoadjuvant Chemotherapy Have Risks in Bladder Cancer
Several factors, including race, insurance, and type of facility, were associated with delays in neoadjuvant chemotherapy treatment for bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Treatment Response Foretells Events in Breast Cancer Treatment Response Foretells Events in Breast Cancer
A pathological complete response to neoadjuvant therapy is a harbinger of an excellent prognosis for most tumor types in breast cancer.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 6, 2018 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

SABCS: T - DM1 Cuts Recurrent Invasive HER2 + Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

SABCS: T-DM1 Cuts Recurrent Invasive HER2 & #43; Breast CA Risk
WEDNESDAY, Dec. 5, 2018 -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
(American Association for Cancer Research) Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Adjuvant chemo might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemo
(American Association for Cancer Research) Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk and higher overall survival in breast cancer patients, and pCR after neoadjuvant chemotherapy had similar association with improved outcomes among those who received additional chemotherapy following surgery (adjuvant chemotherapy) versus those who did not, according to meta-analyses of data from 52 clinical trials, presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

What's Hot at SABCS 2018 What's Hot at SABCS 2018
At the world ’ s largest breast cancer meeting, studies on treatment duration, optimal sequencing, and novel neoadjuvant strategies are all on the agenda.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Chemotherapy or Upfront Surgery in Advanced Ovarian Cancer?
A pooled analysis of two randomized trials found that neoadjuvant chemotherapy and upfront debulking surgery yield similar outcomes in patients with advanced tubo-ovarian cancer, except in some settings. (Source: CancerNetwork)
Source: CancerNetwork - November 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Groundbreaking Results With Pembrolizumab Plus Surgery in Bladder Cancer
The PURE-01 study showed that neoadjuvant pembrolizumab before surgery could downstage disease in muscle-invasive bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - November 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

What Is the Role of EGFR TKIs in Stage III NSCLC?
Previous research showed that gefitinib can improve DFS in certain NSCLC patients, raising the possibility that EGFR-targeted TKIs could be beneficial in the neoadjuvant setting. (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma
(MedPage Today) -- Good survival outcomes, but high rates of toxicities, with ipilimumab-nivolumab combo (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 12, 2018 Category: Dermatology Source Type: news

Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage three melanoma
(University of Texas M. D. Anderson Cancer Center) Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage three melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2018 Category: International Medicine & Public Health Source Type: news

Do Dose-Dense Neoadjuvant Chemo Regimens Improve Responses in Bladder Cancer?
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Timing of DWI-MRI predicts breast cancer response
Diffusion-weighted MR images acquired 12 weeks after the start of neoadjuvant...Read more on AuntMinnie.comRelated Reading: Breast cancer follow-up imaging varies widely Breast MRI underutilized in high-risk women Multiparametric MRI shines for suspected breast cancer Is screening breast MRI being used in the wrong women? Breast MRI technique helps cancer detection without contrast (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 11, 2018 Category: Radiology Source Type: news

Which Is Best Neoadjuvant Chemo in Bladder Cancer? Which Is Best Neoadjuvant Chemo in Bladder Cancer?
A nonstandard neoadjuvant chemotherapy was associated with higher complete response rates and more downstaging in patients with muscle-invasive bladder cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mayo Clinic physicians receive Stand up to Cancer Catalyst Award for melanoma research
This study, ?Neoactivate?, will test two novel approaches to the treatment of patients with high-risk, stage 3 melanoma guided by specific mutations within [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - September 6, 2018 Category: Hospital Management Source Type: news

' Compelling' Regimen for Resectable Advanced-Stage Melanoma'Compelling' Regimen for Resectable Advanced-Stage Melanoma
Dr Weber reviews a new trial comparing neoadjuvant and adjuvant dual MEK/BRAF inhibition to standard of care in advanced resectable melanoma.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 16, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Score as Surrogate for DFS in Rectal Cancer Neoadjuvant Score as Surrogate for DFS in Rectal Cancer
A score incorporating categories for disease-free survival can help clinicians make faster decisions about treatment for rectal cancer.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Improving Surgery for Mesothelioma with Glowing Tumor Technology
Thoracic surgeon Dr. Sunil Singhal at the Abramson Cancer Center has developed glowing tumor technology that should increase the effectiveness of aggressive surgery for malignant pleural mesothelioma. Singhal has shown recently that by adding a contrast agent that makes tumor cells glow, a more complete surgery can be done. This potentially avoids the now almost-inevitable cancer recurrence. “This is a big deal. We could potentially help a lot of patients with this,” Singhal told Asbestos.com. “It could change the entire field [of surgery for mesothelioma].” Singhal and his colleagues from the Abram...
Source: Asbestos and Mesothelioma News - August 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

New RCT Favors Standard of Care for Squamous Cervical Cancer New RCT Favors Standard of Care for Squamous Cervical Cancer
Neoadjuvant chemotherapy falls short of chemoradiation in this new study.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Implications of CTCs in Early Breast Cancer Implications of CTCs in Early Breast Cancer
Can CTCs be used to predict prognosis and response to neoadjuvant chemotherapy in nonmetastatic breast cancer?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Higher OS With Neoadjuvant Chemo-RT in Pancreatic Cancer
In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Cancer Network Editors Source Type: news

Chemoradiation Prevails in Cervical Cancer Trial
(MedPage Today) -- Reduced disease-free survival with neoadjuvant chemotherapy plus surgery (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 15, 2018 Category: OBGYN Source Type: news

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Ericson Stoen, MD, Peter Kabos, MD, Kelly C. Borden, MD, Regina J. Brown, MD, Virginia F. Borges, MD, MMSc, Jennifer R. Diamond, MD Source Type: news

Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo Race May Be Factor in Completion of Neoadjuvant Breast CA Chemo
White women with breast cancer are more likely to complete their neoadjuvant chemotherapy regimen than women of color, a U.S. study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant CRT May Improve Survival in Pancreatic Cancer Neoadjuvant CRT May Improve Survival in Pancreatic Cancer
Results are preliminary, but patients who received neoadjuvant chemoradiation had better outcomes than did those who had immediate surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
Dave LevitanJun 6, 2018The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Dose-Dense Chemo Shows Promise as Neoadjuvant Therapy in Bladder Cancer
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Source Type: news

Nodal Response to Pre-Op Tx Tied to Survival in Esophageal Cancer
WEDNESDAY, May 2, 2018 -- For patients with locally advanced esophageal cancer, the status of lymph nodes following preoperative neoadjuvant chemotherapy or chemoradiation therapy determines survival, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 2, 2018 Category: Pharmaceuticals Source Type: news

For patients with esophageal cancer, status of lymph nodes after preoperative therapy determines survival
(American Association for Thoracic Surgery) The status of lymph nodes rather than the status of the primary tumor following preoperative neoadjuvant chemotherapy or chemoradiation therapy is the most important factor that determines whether patients with locally advanced esophageal cancer will survive. The study presented at the AATS 98th Annual Meeting indicates that while preoperative chemotherapy and radiation therapy improve survival of patients with esophageal cancer, patients with malignant lymph nodes following therapy were less likely to survive than patients with no cancer in the lymph nodes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2018 Category: Cancer & Oncology Source Type: news

Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy
Adjuvant chemotherapy is associated with improved overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures
Among the new data on immunotherapy for lung cancer presented at the recent AACR meeting, the potential role of immune checkpoint inhibitors in the neoadjuvant setting may be the most promising.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes
Circulating tumor cell (CTC) count independently predicts outcomes in women with early breast cancer treated with neoadjuvant chemotherapy, according to a meta-analysis.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 24, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Improved Pancreatic Survival Seen After Neoadjuvant Therapy and Surgery Improved Pancreatic Survival Seen After Neoadjuvant Therapy and Surgery
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Neoadjuvant Anti-PD-1 Active in Multiple Tumors (CME/CE)
(MedPage Today) -- Major responses in pilot study for NSCLC, melanoma, bladder cancers (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 18, 2018 Category: Dermatology Source Type: news

Neoadjuvant Nivolumab Shows Benefit in NSCLC Neoadjuvant Nivolumab Shows Benefit in NSCLC
Already used for nonresectable lung cancer, immunotherapy is now heading for the neoadjuvant niche, with nivolumab showing benefit when used before surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

TNT Is Viable for Locally Advanced Rectal Cancer
CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news

Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer
Preoperative chemotherapy in combination with chemoradiation (total neoadjuvant therapy, or TNT) appears to have advantages over traditional approaches to treating locally advanced rectal cancer, according to new research.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Some HER2+ Breast Cancer Patients Could Avoid SLNB Following Neoadjuvant Therapy
Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer
Carboplatin should be considered as a potential component of neoadjuvant chemotherapy for women with high-risk, triple-negative breast cancer, regardless of BRCA status, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Biomarkers to Predict Treatment Response in Bladder Cancer Biomarkers to Predict Treatment Response in Bladder Cancer
A new study looks at whether certain biomarkers may predict response to adjuvant and neoadjuvant treatments for bladder cancer.Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2018 Category: Consumer Health News Tags: Urology Journal Article Source Type: news